ClinicalTrials.gg
CompletedNCT07271251Updated Aug 13, 2026

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

A Phase 3 interventional study of Oral semaglutide in Type 2 Diabetes, sponsored by Novo Nordisk A/S. Completed at 15 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
59th of 163
267 · median 104
Started
2025
with 9 others
Phase 3
57 of 163
7 open now
Registered
151st of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 59th largest by enrollment, is one of 10 that started in 2025, is one of 57 in phase 3, and was the 151st registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Japanese male or female.
  • Age 18 years or above at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥) 90 days prior to day of screening.
  • (HbA1c) of 7.0-10.5 percent (%) (53-91 millimoles per mole [mmol /mol]) (both inclusive) at screening.
  • Stable daily dose(s) ≥ 60 days before screening with any 1-2 of the following oral antidiabetic drugs (OADs): Sulfonylurea (SU), glinide, thiazolidinedione (TZD), alpha-glucosidase inhibitor (α-GI), sodium-glucose cotransporter 2 (SGLT-2) inhibitor or metformin (effective or maximum tolerated dose as judged by the investigator) according to Japanese labelling.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Previous participation in this study. Participation is defined as signed .
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • Current participation (i.e., signed informed consent) in any other interventional clinical study.
  • Exposure to an medicinal product within 90 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
  • Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
  • Previous or planned (during the study period) obesity treatment with surgery or a weight loss device.
  • Anticipated initiation or change in concomitant medications for more than 14 consecutive days affecting weight or glucose metabolism.
  • Use of any medication with unknown or unspecified content within 90 days before screening.
  • Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
  • Presence of gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.
  • History or presence of pancreatitis (acute or chronic).
  • History of major surgical procedures involving the stomach potentially affecting absorption of study products or current presence of gastrointestinal implant.
  • Myocardial infarction, stroke, or hospitalization for unstable angina pectoris within 60 days before screening.
  • Chronic heart failure classified as being in (NYHA) Class IV at screening.
  • Planned coronary, carotid or peripheral artery revascularisation.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified within 90 days before screening or in the period between screening and randomisation.
  • Impaired liver function, defined as (ALT) ≥ 2.5 times or >1.5 times upper normal limit at screening.
  • Renal impairment with estimated (eGFR) less than (\<) 30 millilitres per minute per meter square (mL/min/1.73 m\^2) as per 2021 Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) formula (by creatinine) at screening.
  • Treatment with medication for diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Presence or history of malignant neoplasms or in situ carcinomas within 5 years before screening.
  • Any episodes of diabetic ketoacidosis within 90 days before screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Oral semaglutide D

    Participants will receive oral semaglutide D once daily.

    Drug: Oral semaglutide

  • Experimental
    Oral semaglutide

    Participants will receive oral semaglutide once daily.

    Drug: Oral semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c).

    Measured in percentage (%)-point.

    Time frame: From baseline (week 0) to end of treatment (week 20)

Secondary outcomes

  1. Change in body weight

    Measured in Kilogram (Kg).

    Time frame: From baseline (week 0) to end of treatment (week 20)

  2. Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 25)

07

Study locations

15 sites
  • Seino Internal Medicine Clinic_Internal medicine
    Koriyama-shi, Fukushima, Fukushima, Japan 963-8851, Japan
  • Hayashi Diabetes Clinic_Internal Medicine and Diabetes Medicine
    Chigasaki-shi, Kanagawa, Japan 253-0044, Japan
  • Jinnouchi Hospital_Internal Medicine
    Kumamoto, Kumamoto, Japan 862-0976, Japan
  • Heiwadai Hospital_Internal Medicine
    Miyazaki, Miyazaki 880-0034, Japan
  • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
    Aichi, 468-0009, Japan
  • Tokuyama clinic_Diabetic internal medicine
    Chiba, 261-0004, Japan
  • Futata Tetsuhiro Clinic Meinohama_Internal medicine
    Fukuoka-shi, Fukuoka, 819-0006, Japan
  • Oodouri Diabetes, Internal medicine Clinic_Internal Medicine, Diabetes Internal Medicine
    Hokkaido, 060-0001, Japan
  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
  • Yokohama Minoru Clinic_Internal medicine
    Kanagawa, 232-0064, Japan
  • Shonan Takai Clinic_Internal Medicine
    Kanagawa, 247-0055, Japan
  • Soka Sugiura Internal Medicine Clinic
    Soka-shi, Saitama, 340-0015, Japan
  • Oyama East Clinic_Internal Medicine
    Tochigi, 323-0022, Japan
  • Tokyo-Eki Center-building Clinic_Internal Medicine
    Tokyo, 103-0027, Japan
  • Kato Clinic of Internal Medicine_Internal Medicine
    Tokyo, 125-0054, Japan
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jun 2026, 6 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 6 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 9, 2025
StartActual
Dec 1, 2025
Primary completionActual
Jun 29, 2026
CompletionActual
Aug 4, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07271251
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Dec 1, 2025
Primary completion
Jun 29, 2026
Completion
Aug 4, 2026
Last update
Aug 13, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion